~~WHAT IS CLAIMED IS:~~**CLAIMS**

1. ~~A method of~~A liquid composition comprising botulinum neurotoxin (BoNT) for use in treating moderate to severe glabellar lines (GL) and/or lateral canthal lines (LCL) in a human subject, ~~comprising administering a therapeutically effective amount of a liquid composition comprising a botulinum neurotoxin to the subject, thereby reducing the appearance of moderate to severe GL and/or LCL, wherein the liquid composition further comprises 1-5 buffering agents, at least one stabilizer, and at least one surfactant.~~

~~2. The method of claim 1, where the~~ wherein said liquid composition further comprises ~~at least 4 buffering agents.~~

~~3. The method of claim 1 or 2, wherein the liquid composition comprises~~the following components to provide a ~~first buffering agent present at a concentration of about 100 to about 300 mM, or at a concentration of about 0.1-10 mg/mL.~~liquid formulation of BoNT that is stable when stored:

~~4. The method~~a. a source of ~~claim 3, wherein the liquid composition comprises a second buffering agent present~~chloride ions selected from NaCL at ~~a~~ concentration of ~~about 1 to about 25~~100-300 mM, ~~or~~and KCl at a concentration of ~~about 0.1-1.0 mg/mL.~~

~~5. The method of claim 4, wherein the liquid composition comprises a third buffering agent present at a concentration of about 1 to about~~ 1-25 mM~~, or at a concentration of about 0.1-1.0 mg/mL.~~;

~~6. The method of claim 5, wherein the liquid composition comprises a fourth buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.~~

~~7. The method of claim 6, wherein the liquid composition comprises a fifth buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.~~

~~8. The method of any one of claims 1-7, wherein the buffering agents are selected from the group consisting of sodium chloride, potassium chloride,~~ b. more than one source of phosphate ions selected from sodium phosphate, potassium phosphate, di-sodium hydrogen phosphate, dehydrate, and sodium dihydrogen phosphate dehydrate~~.~~, at a concentration of 1-50 mM;

~~9. The method~~c. a non-ionic surfactant at a concentration of ~~any one of claims 1-8, wherein the at least one stabilizer is~~0.01-5% (v/v); and

d. an amino acid~~.~~

~~10. The method of claim 9, wherein the amino acid is~~ stabilizer selected from ~~the group consisting of~~ alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan~~.~~, at a concentration of 0.1-3mg/ml.

~~11. The method of claim 9 or 10~~2. The liquid composition for use according to claim 1, wherein the composition comprises more than one source of chloride ions.

3. The liquid composition for use of claim 1 or claim 2, wherein the amino acid is in the L isoform.

4. The liquid composition for use of any one of the preceding claims, wherein the amino acid is ~~in the D isoform or the L isoform~~present at a concentration of about 0.75 to about 2.25 mg/mL.

~~12~~5. The ~~method~~liquid composition for use of any one of ~~claims 9-11, wherein the amino acid is present at a concentration of about 0.1 to about 3.0 mg/mL.~~

~~13. The method of any one of claims 1-12, wherein the at least one surfactant is a non-ionic surfactant.~~

~~14. The method of claim 13~~the preceding claims, wherein the non-ionic surfactant is ~~present at a concentration of about 0.01% (v/v) to about 5.0% (v/v), or at a concentration of about 0.1 to about 3.0 mg/mL~~a polysorbate.

~~15~~6. The ~~method~~liquid composition for use of any one of the preceding claims ~~1-14~~, wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin types A, B, C, D, E, F and G~~.~~; preferably

~~16. The method of claim 15,~~ wherein the botulinum neurotoxin is botulinum neurotoxin type A.

~~17~~7. The ~~method~~liquid composition for use of any one of the preceding claims ~~1-16~~, wherein the pH of the liquid composition is between 6.6 and 6.9.

~~18~~8. The ~~method~~liquid composition for use of any one of the preceding claims ~~1-17, wherein the botulinum neurotoxin has a molecular weight of about 150 kDa.~~

~~19. The method of any one of claims 1-18~~, wherein the osmolality of the liquid composition is between 270 mosm/kg and 310 mosm/kg.

~~20~~9. The ~~method~~liquid composition for use of any one of any one of the preceding claims ~~1-19~~, wherein between 1 and 100 units of botulinum toxin is administered to the subject~~.~~

~~21. The method of claim 20,~~, wherein 1 Unit is an amount of the botulinum neurotoxin corresponds to the calculated median lethal dose (LD50) in mice; optionally wherein:

a) between 10 and 75 units of botulinum toxin is administered to the subject.

~~22. The method of claim 20, wherein~~ b) between 25 and 75 units of botulinum toxin is administered to the subject~~.~~; or

~~23. The method of claim 20, wherein~~ c) 10, 25, 30, 45, 50, 60, 75, or 90 units of botulinum toxin is administered to the subject.

~~24~~10. The ~~method~~liquid composition for use of any one of the preceding claims ~~1-23~~, wherein the liquid composition is administered by ~~injection.~~

~~25. The method of claim 24, wherein the injection is~~ subdermal, transdermal, intradermal or intramuscular~~.~~ injection; optionally

~~26. The method of claim 24 or 25,~~ wherein the subject is injected multiple times in the glabellar region.

~~27~~11. The ~~method~~liquid composition for use of claim ~~26~~10, wherein adjacent injections are separated by about 0.5 to about 10 cm~~.~~

~~28. The method of claim 26,~~; or wherein adjacent injections are separated by about 1.5 to about 3 cm.

~~29~~12. The ~~method~~liquid composition for use of any one of claims ~~26-28~~10-11, wherein the injections are in the procerus muscle and the corrugator supercillii muscles on each side of the face~~.~~

~~30. The method of claim 29~~, wherein the injections are first made in the procerus muscle followed by the corrugator supercillii muscles on each side of the face, moving outwards from the median.

~~31~~13. The ~~method~~liquid composition for use of any one of claims ~~26-30~~10-12, wherein all the injections are about 1 cm above the upper orbital rim and internal to the mid-pupillary lines~~.~~; and/or

~~32. The method of any one of claims 26-31,~~ wherein all the injections are at least 1 cm above the central eyebrow or the bony supraorbital ridge~~.~~; and/or

~~33. The method of any one of claims 26-32,~~ further comprising applying pressure on the upper orbital rim while injecting to minimize risks of regional effect of the botulinum neurotoxin~~.~~; and/or

~~34. The method of claim 26 or 27, wherein the subject is injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.~~

~~35. The method of any one of claims 26-33,~~ wherein the subject is further injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

~~36~~14. The ~~method~~liquid composition for use of claim 10, wherein the subject is injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

15. The liquid composition for use of any one of the preceding claims~~ 1-35~~, wherein said ~~method~~treatment is repeated at intervals from about 1 month to about 6 months to inhibit said recurrence~~.~~; optionally

~~37. The method of claim 36,~~ wherein said ~~method~~treatment is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence~~.~~; or

~~38. The method of claim 36,~~ wherein said ~~method~~treatment is repeated at intervals of about 4 months to inhibit said recurrence.

~~39. A liquid composition comprising a botulinum neurotoxin and 1-5 buffering agents, at least one stabilizer, and at least one surfactant for use in treating glabellar lines and/or lateral canthal lines in a subject.~~

~~40. Use of a liquid composition comprising a botulinum neurotoxin and 1-5 buffering agents, at least one stabilizer, and at least one surfactant for treating glabellar lines and/or lateral canthal lines comprising administering the liquid composition to a subject in need thereof.~~